Visual Acuity — Evaluation of Letters Versus Numbers (ELEVEN) Study
Citation(s)
Bailey IL, Lovie JE New design principles for visual acuity letter charts. Am J Optom Physiol Opt. 1976 Nov;53(11):740-5.
Chaikitmongkol V, Nanegrungsunk O, Patikulsila D, Ruamviboonsuk P, Bressler NM Repeatability and Agreement of Visual Acuity Using the ETDRS Number Chart, Landolt C Chart, or ETDRS Alphabet Chart in Eyes With or Without Sight-Threatening Diseases. JAMA Ophthalmol. 2018 Mar 1;136(3):286-290. doi: 10.1001/jamaophthalmol.2017.6290.
Doig GS, Simpson F Randomization and allocation concealment: a practical guide for researchers. J Crit Care. 2005 Jun;20(2):187-91; discussion 191-3.
Ferris FL 3rd, Bailey I Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum. Ophthalmology. 1996 Jan;103(1):181-2.
Kniestedt C, Stamper RL Visual acuity and its measurement. Ophthalmol Clin North Am. 2003 Jun;16(2):155-70, v. Review.
Koenig S, Tonagel F, Schiefer U, Bach M, Heinrich SP Assessing visual acuity across five disease types: ETDRS charts are faster with clinical outcome comparable to Landolt Cs. Graefes Arch Clin Exp Ophthalmol. 2014 Jul;252(7):1093-9. doi: 10.1007/s00417-014-2670-y. Epub 2014 May 28.
Kuo HK, Kuo MT, Tiong IS, Wu PC, Chen YJ, Chen CH Visual acuity as measured with Landolt C chart and Early Treatment of Diabetic Retinopathy Study (ETDRS) chart. Graefes Arch Clin Exp Ophthalmol. 2011 Apr;249(4):601-5. doi: 10.1007/s00417-010-1461-3. Epub 2010 Jul 24.
Ruamviboonsuk P, Tiensuwan M, Kunawut C, Masayaanon P Repeatability of an automated Landolt C test, compared with the early treatment of diabetic retinopathy study (ETDRS) chart testing. Am J Ophthalmol. 2003 Oct;136(4):662-9.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
